• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Scand J Immunol . Decreased neutrophil-mediated bacterial killing in COVID-19 patients

tetano

Editor, Senior Moderator
Scand J Immunol


. 2021 Sep;94(3):e13083.
doi: 10.1111/sji.13083. Epub 2021 Jun 11.
Decreased neutrophil-mediated bacterial killing in COVID-19 patients


Masoumeh Nomani[SUP] 1 [/SUP], Mohammad Varahram[SUP] 2 [/SUP], Payam Tabarsi[SUP] 1 [/SUP], Seyed MohammadReza Hashemian[SUP] 3 [/SUP], Hamidreza Jamaati[SUP] 3 [/SUP], Majid Malekmohammad[SUP] 3 [/SUP], Mona Ghazi[SUP] 4 [/SUP], Ian M Adcock[SUP] 5 [/SUP], Esmaeil Mortaz[SUP] 1 [/SUP]



Affiliations

Abstract

The coronavirus disease COVID-19 was first described in December 2019. The peripheral blood of COVID-19 patients have increased numbers of neutrophils which are important in controlling the bacterial infections observed in COVID-19. We sought to evaluate the cytotoxic capacity of neutrophils in COVID-19 patients. 34 confirmed COVID-19 patients (29 severe, five mild disease), and nine healthy controls were recruited from the Masih Daneshvari Hospital (Tehran, Iran) from March to May 2020. Polymorphonuclear (PMN) cells were isolated from whole blood and incubated with green fluorescent protein (GFP)-labelled methicillin-resistant Staphylococcus aureus (SA) and Pseudomonas aeruginosa (PA). Bacterial growth was determined by measuring the florescence of co-cultures of bacteria and neutrophils and reported as the lag time before exponential growth. The number of viable bacteria was determined after 70 hours as colony-forming units (CFU). The immunophenotype of tested cells was evaluated by flow cytometry. Isolated neutrophils have higher surface expression of CD16 and CD62L with negative markers for PMN-MDSC. Bacterial growth in the presence of SA (22 ± 0.9 versus 9.2 ± 0.5 h, P < .01) and PA (12.4 ± 0.6 versus 4.5 ± 0.22, P < .01) was significantly reduced in COVID-19 patients. After 70 h incubation of PMN with bacteria (SA and PA), CFUs were significant increased in COVID-19 patients SA (2.6 ± 0.09 × 10[SUP]8[/SUP] CFU/mL-severe patients and 1.4 ± 0.06 × 10[SUP]8[/SUP] CFU/mL-mild patients, P < .001) and PA (2.2 ± 0.09 × 10[SUP]9[/SUP] CFU/mL-severe patients and 1.6 ± 0.03 × 10[SUP]9[/SUP] CFU/mL-mild patients, P < .001). Gentamycin proliferation assays confirmed the presence of intracellular bacteria. Reduced bacterial killing by neutrophils from COVID-19 patients may be responsible for the high bacterial yield seen in these patients.

Keywords: COVID‐19; PMN‐MDSCs; Pseudomonas aeruginosa; Staphylococcus aureus; colony‐forming unit; polymorphonuclear.
 
Back
Top Bottom